ENTA · Enanta Pharmaceuticals Inc · Documents
Market Cap
$377.47M
Shares
29.13M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-12 | 2026-06-30 | |
| 8-K | 2026-08-10 | — | |
| 8-K | 2026-07-02 | — | |
| 8-K | 2026-06-23 | — | |
| 8-K | 2026-06-18 | — | |
| Investor Event Transcript | 2026-06-04 | 2026-03-31 | |
| 10-Q | 2026-05-13 | 2026-03-31 | |
| 8-K | 2026-05-11 | — | |
| 8-K | 2026-03-26 | 2026-03-20 | |
| 8-K | 2026-03-12 | 2026-03-11 | |
| 10-Q | 2026-02-11 | 2025-12-31 | |
| 8-K | 2026-02-09 | — | |
| DEF 14A | 2026-01-26 | 2026-03-11 | |
| 10-K | 2025-11-19 | 2025-09-30 | |
| 8-K | 2025-11-17 | — | |
| 8-K | 2025-10-01 | 2025-09-30 | |
| 8-K | 2025-09-29 | — | |
| 8-K | 2025-09-29 | — | |
| 8-K | 2025-08-27 | 2025-08-26 | |
| 8-K | 2025-08-20 | — | |
| 10-Q | 2025-08-13 | 2025-06-30 | |
| 8-K | 2025-08-11 | — | |
| 10-Q | 2025-05-14 | 2025-03-31 | |
| 8-K | 2025-05-12 | — | |
| 8-K | 2025-03-17 | 2025-03-13 | |
| 10-Q | 2025-02-12 | 2024-12-31 | |
| 8-K | 2025-02-10 | — | |
| DEF 14A | 2025-01-27 | 2025-03-13 | |
| 8-K | 2024-12-09 | — | |
| 10-K | 2024-11-27 | 2024-09-30 | |
| 8-K | 2024-11-25 | — | |
| 10-Q | 2024-08-07 | 2024-06-30 | |
| 8-K | 2024-08-05 | — | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| 8-K | 2024-05-06 | — | |
| 8-K | 2024-03-12 | 2024-03-06 | |
| 10-Q | 2024-02-08 | 2023-12-31 | |
| 8-K | 2024-02-07 | — | |
| DEF 14A | 2024-01-26 | 2024-03-06 | |
| 8-K | 2023-12-26 | 2023-12-19 | |
| 10-K | 2023-11-22 | 2023-09-30 | |
| 8-K | 2023-11-20 | — | |
| 10-Q | 2023-08-08 | 2023-06-30 | |
| 8-K | 2023-08-07 | — | |
| 8-K | 2023-06-07 | — | |
| 10-Q | 2023-05-09 | 2023-03-31 | |
| 8-K | 2023-05-08 | — | |
| 8-K | 2023-04-27 | 2023-04-25 | |
| 8-K | 2023-03-10 | — | |
| 8-K | 2023-03-07 | 2023-03-02 |
Showing 1–50 of 92 filings
Key facts
CIK
1177648
CUSIP
29251M106
13F (30d)
40 filings
40 filers
Visit website
Investor relations